Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 3 completed upper quartile by trial count

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): 5 sponsored US clinical trials, none currently recruiting.

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 1 trials.

Upper-quartile sponsor footprint

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

TERMINATED Phase 3

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

NCT04095858
TERMINATED Phase 2

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

NCT03960541
COMPLETED Phase 3

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
COMPLETED Phase 2

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

NCT02663622
COMPLETED Phase 1

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

NCT02650895

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 2

Therapeutic Areas

Healthy Volunteers 1

How the Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) archive is shaped

5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).

Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Healthy Volunteers (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) page

5 registered trials is a research-attention snapshot, not an endorsement of Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) or any single study.

  • None of Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Volunteers is the condition Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.